Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks

被引:348
作者
Arnsten, Amy F. T. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA
关键词
Atomoxetine; dopamine; guanfacine; methylphenidate; norepinephrine; working memory; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; WORKING-MEMORY PERFORMANCE; DEFICIT HYPERACTIVITY DISORDER; DOPAMINE-BETA-HYDROXYLASE; D1 RECEPTOR ACTIONS; NEURONS IN-VITRO; AGED MONKEYS; RESPONSE-INHIBITION; COGNITIVE FUNCTION; PYRAMIDAL NEURONS;
D O I
10.1016/j.biopsych.2011.01.027
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The symptoms of attention-deficit/hyperactivity disorder (ADHD) involve impairments in prefrontal cortical top-down regulation of attention and behavior. All current pharmacological treatments for ADHD facilitate catecholamine transmission, and basic research suggests that these compounds have prominent actions in the prefrontal cortex (PFC). The dorsolateral PFC is especially sensitive to levels of norepinephrine and dopamine, whereby either too little or too much markedly impairs PFC function. Recent physiological studies have shown that norepinephrine strengthens PFC network connectivity and maintains persistent firing during a working memory task through stimulation of postsynaptic alpha(2A)-adrenoceptors on PFC neurons. Conversely, dopamine acts at D1 receptors to narrow spatial tuning, sculpting network inputs to decrease noise (i.e., stabilization of the representation). The stimulant medications and atomoxetine appear to enhance PFC function by indirectly increasing these catecholamine actions through blockade of norepinephrine and/or dopamine transporters. In contrast, guanfacine mimics the enhancing effects of norepinephrine at postsynaptic alpha(2A)-receptors in the PFC, strengthening network connectivity. Stronger PFC regulation of attention, behavior, and emotion likely contributes to the therapeutic effects of these medications for the treatment of ADHD.
引用
收藏
页码:E89 / E99
页数:11
相关论文
共 141 条
[1]  
ARNSTEN A F T, 1990, Society for Neuroscience Abstracts, V16, P164
[2]  
Arnsten AF., 2009, DOPAMINE HDB, P230, DOI [10.1093/acprof:oso/9780195373035.003.0016, DOI 10.1093/ACPROF:OSO/9780195373035.003.0016]
[3]   STRESS PRODUCES OPIOID-LIKE EFFECTS ON INVESTIGATORY BEHAVIOR [J].
ARNSTEN, AFT ;
BERRIDGE, C ;
SEGAL, DS .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1985, 22 (05) :803-809
[4]  
ARNSTEN AFT, 1995, J NEUROSCI, V15, P3429
[5]   α-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function [J].
Arnsten, AFT ;
Mathew, R ;
Ubriani, R ;
Taylor, JR ;
Li, BM .
BIOLOGICAL PSYCHIATRY, 1999, 45 (01) :26-31
[6]   Through the looking glass: Differential noradenergic modulation of prefrontal cortical function [J].
Arnsten, AFT ;
Simon, F .
NEURAL PLASTICITY, 2000, 7 (1-2) :133-146
[7]  
ARNSTEN AFT, 1988, J NEUROSCI, V8, P4287
[8]   ALPHA-2 ADRENERGIC AGONISTS DECREASE DISTRACTIBILITY IN AGED MONKEYS PERFORMING THE DELAYED-RESPONSE TASK [J].
ARNSTEN, AFT ;
CONTANT, TA .
PSYCHOPHARMACOLOGY, 1992, 108 (1-2) :159-169
[9]   The alpha-1 adrenergic agonist, cirazoline, impairs spatial working memory performance in aged monkeys [J].
Arnsten, AFT ;
Jentsch, JD .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 58 (01) :55-59
[10]   ALPHA-2-ADRENERGIC MECHANISMS IN PREFRONTAL CORTEX ASSOCIATED WITH COGNITIVE DECLINE IN AGED NONHUMAN-PRIMATES [J].
ARNSTEN, AFT ;
GOLDMANRAKIC, PS .
SCIENCE, 1985, 230 (4731) :1273-1276